Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 18, 2015 3:33 AM ET

Healthcare Equipment and Supplies

Company Overview of Sebacia, Inc.

Company Overview

Sebacia, Inc., a medical device company, focuses on creating light-based therapies for the treatment of dermatological conditions. It is developing a device for the treatment of acne. Sebacia, Inc. was formerly known as TIF Acquisition XII, Inc. The company was incorporated in 2008 and is based in Duluth, Georgia.

2905 Premiere Parkway

Suite 150

Duluth, GA 30097

United States

Founded in 2008





Key Executives for Sebacia, Inc.

President and Director
Executive Officer
Compensation as of Fiscal Year 2014.

Sebacia, Inc. Key Developments

Sebacia, Inc. Announces Positive Results of Two Independent Clinical Studies in Acne

Sebacia, Inc. announced the presentation of positive clinical results from two independent studies conducted in Europe investigating the use of Sebacia gold microparticles to treat acne. The microparticles are proprietarily designed to be used with an approved dermatology laser to reduce the size and activity of sebaceous glands and follicles, which are responsible for acne. The two studies evaluated Sebashell treatment in a total of 97 people with acne. The studies were designed as 1:1 randomization with crossover control groups. The control arm in the first study was over-the-counter face wash and in the second study was the suspension without Sebacia microparticles and laser treatment. Results showed significant reduction in inflammatory lesions and IGA scores in the treated arm versus the control arms at 12 weeks post baseline in both studies. Inflammatory lesion count reduction was approximately 60% at six months post baseline, indicating robust durability. Treatment was well tolerated, and side effects were limited to transient mild erythema (redness) and mild edema (swelling).

Similar Private Companies By Industry

Company Name Region
MetroSleep Inc. United States
American Medical Devices, Inc. United States
Titan Spine, LLC United States
SpringMed Group, LLC United States
Guardian Scientific, Inc. United States

Recent Private Companies Transactions

Private Placement
May 30, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sebacia, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at